JP2013531681A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531681A5
JP2013531681A5 JP2013518858A JP2013518858A JP2013531681A5 JP 2013531681 A5 JP2013531681 A5 JP 2013531681A5 JP 2013518858 A JP2013518858 A JP 2013518858A JP 2013518858 A JP2013518858 A JP 2013518858A JP 2013531681 A5 JP2013531681 A5 JP 2013531681A5
Authority
JP
Japan
Prior art keywords
seq
functional variant
nucleic acid
use according
e4orf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518858A
Other languages
English (en)
Japanese (ja)
Other versions
JP5965397B2 (ja
JP2013531681A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/043338 external-priority patent/WO2012006512A1/en
Publication of JP2013531681A publication Critical patent/JP2013531681A/ja
Publication of JP2013531681A5 publication Critical patent/JP2013531681A5/ja
Application granted granted Critical
Publication of JP5965397B2 publication Critical patent/JP5965397B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518858A 2010-07-08 2011-07-08 非アルコール性脂肪肝疾患の予防および治療のためのアデノウイルスａｄ３６ｅ４ｏｒｆ１タンパク質 Expired - Fee Related JP5965397B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36244310P 2010-07-08 2010-07-08
US61/362,443 2010-07-08
PCT/US2011/043338 WO2012006512A1 (en) 2010-07-08 2011-07-08 Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease

Publications (3)

Publication Number Publication Date
JP2013531681A JP2013531681A (ja) 2013-08-08
JP2013531681A5 true JP2013531681A5 (enExample) 2014-08-21
JP5965397B2 JP5965397B2 (ja) 2016-08-03

Family

ID=44629893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518858A Expired - Fee Related JP5965397B2 (ja) 2010-07-08 2011-07-08 非アルコール性脂肪肝疾患の予防および治療のためのアデノウイルスａｄ３６ｅ４ｏｒｆ１タンパク質

Country Status (11)

Country Link
US (2) US8951980B2 (enExample)
EP (1) EP2590665B1 (enExample)
JP (1) JP5965397B2 (enExample)
KR (1) KR101831638B1 (enExample)
CN (1) CN103052397B (enExample)
AU (1) AU2011274537B9 (enExample)
CA (1) CA2803787C (enExample)
ES (1) ES2550962T3 (enExample)
NZ (1) NZ606236A (enExample)
TW (1) TWI531650B (enExample)
WO (1) WO2012006512A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062794A1 (en) 2012-10-17 2014-04-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for improving glucose uptake
US9354963B2 (en) * 2014-02-26 2016-05-31 Microsoft Technology Licensing, Llc Service metric analysis from structured logging schema of usage data
US10047107B2 (en) 2014-04-23 2018-08-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Small molecule analogs of E4orf1
GB201910299D0 (en) * 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004004775T2 (de) * 2004-08-12 2007-11-22 Roche Diagnostics Gmbh Verfahren zur Diagnose von Leberfibrose.
US20060045919A1 (en) 2004-08-27 2006-03-02 Samueli Institute Homeopathic compositions and methods for the treatment of cancer
JP2008105945A (ja) * 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
ES2472325T3 (es) * 2005-11-30 2014-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Gen y proteína del adenovirus 36 E4 orf 1 y sus usos
WO2007120362A2 (en) * 2005-12-27 2007-10-25 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
JP2008273938A (ja) * 2007-03-30 2008-11-13 Shiseido Co Ltd アディポネクチン産生促進剤

Similar Documents

Publication Publication Date Title
Amet et al. Human growth hormone–transferrin fusion protein for oral delivery in hypophysectomized rats
Jiang et al. Biomimetic nanovesicles as a dual gene delivery system for the synergistic gene therapy of Alzheimer’s disease
Ferrari et al. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis
JP6924744B2 (ja) Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用
Poelstra et al. Drug targeting to the diseased liver
US20180258429A1 (en) Sarna compositions and methods of use
Duan et al. Exosome-mediated drug delivery for cell-free therapy of osteoarthritis
JP2018520646A5 (enExample)
JP2019523648A5 (enExample)
SI2823048T1 (en) A new drug delivery system based on JCV-VLP
Devaney et al. Clinical review: gene-based therapies for ALI/ARDS: where are we now?
JP2024540994A5 (enExample)
Xie et al. Pulmonary delivery of siRNA via polymeric vectors as therapies of asthma
JP2021533825A5 (enExample)
Chen et al. Using RNA therapeutics to promote healthy aging
EP2701723A2 (en) Dna aptamers for promoting remyelination
EP2822600A1 (en) Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
WO2021042944A1 (zh) 肌肉靶向的微环dna基因治疗
Hirose et al. Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes
US20260109963A1 (en) Compositions, systems, and methods for reducing adipose tissue
ES2559106B1 (es) Método de activación de la expresión del gen Pitx2 para promover la regeneración muscular
Janssen et al. Gene based therapies for kidney regeneration
McCarthy et al. Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy
JP2015505535A5 (enExample)
CN116507721A (zh) 构建溶瘤病毒的方法